BOZEMAN, Mont., Aug. 15, 2023 /PRNewswire/ - Microbion Corporation today announced that the company presented a poster highlighting the results from a series of in vitro and in vivo studies characterizing pravibismane's effect against Mycobacteroides abscessus at the recent 6th World Bronchiectasis & NTM Conference held in New York, NY. The studies were conducted by Dr. Luiz Bermudez at Oregon State University and financial support was provided by CARB-X.
BOZEMAN, Mont. and VANCOUVER, BC, March 9, 2023 /PRNewswire/ - Microbion Corporation today announced that a Phase 2, randomized, controlled study has been initiated to assess the safety and efficacy of topical pravibismane for the treatment of subjects with moderate infections of chronic diabetic foot ulcers (DFU). DFU infections are a serious complication of diabetes associated with significant morbidity and mortality. DFU infections are the most frequent diabetic complication requiring hospitalization and may lead to lower extremity amputation if the infection fails to resolve. In 2018, approximately 8.25 million hospital discharges associated with diabetes were reported, including 154,000 for lower-extremity amputation.1 Estimates of 5-year mortality for DFU, minor and major amputations range from 30.5% to 56.6%.2 With the increasing global prevalence of diabetes, novel treatments for DFU infection represent an increasing global unmet need.
BOZEMAN, MT and VANCOUVER, BC, Nov. 3, 2022 /PRNewswire/ - Microbion Corporation today announced that the company will present a poster at the North American Cystic Fibrosis Conference, November 3 – 5, in Philadelphia, PA highlighting the activity of pravibismane against bacterial pathogens associated with lung infection in people with cystic fibrosis (CF). The objective of this study was to measure the minimal inhibitory concentration of pravibismane on pathogens commonly associated with CF lung infections and to determine whether the presence of pulmonary surfactant impacted pravibismane's activity. Pravibismane's activity was compared to a panel of frontline antibiotics clinically used to manage these infections. Financial support for this study was provided by CARB-X.
Funding will support exploratory phase 2 proof-of-concept study in patients hospitalized for moderate to severe diabetic foot ulcer infection (DFI)...
BOZEMAN, Mont., June 1, 2022 /PRNewswire/ - Microbion Corporation today announced that the company will present a poster highlighting the in vitro...